founding in 1970, JDRF has awarded more than $1.6 billion to diabetes research,
including $116 million in FY2011. In FY2011, JDRF funded research projects in
18 countries throughout the world, including 53 clinical trials.
research goals are realized by the projects being supported in three basic
- Cure: Restoring a person's insulin-producing
capability and halting or reversing the body's misguided immune attack on the pancreas.
- Treat: Developing new devices and therapies that
optimize blood sugar control and treat or prevent the complications of T1D.
- Prevent: Preventing T1D from occurring or
stopping the disease process before it damages the pancreas.
Top 10 Research Advances of FY2012
JDRF Cure Research:
Halting the autoimmune process and restoring normal insulin production.
- Targeted Immune Rebalancing Therapy Starts
- An Explosion of Newly Discovered Beta Cell
- Invention of Novel Oxygen-Producing Biomaterial
for Beta Cell Encapsulation
- Blood Test for Beta Cell Death Discovered
JDRF Treat Research:
Developing new devices and therapies that optimize blood sugar control and
treat or prevent T1D complications.
- FDA Issues Draft AP System Guidance as a Result
of JDRF-Led Effort
- JDRF APP Consortium Conducts the First Real
World Test of an Artificial Pancreas System
- JDRF Challenged the World to Invent Glucose
Responsive Insulin Products for T1D
- Novel Markers of Kidney Disease Risk in T1D
JDRF Prevent Research:
Preventing the autoimmune process from starting or stopping it before the onset
of insulin dependence.
- Focused a Novel Vaccine Technology on T1D
- Strengthened the Link between Enteroviruses and